Public Health Emergency - Leading a Nation Prepared
September 13, 2021: Effective, September 13, 2021, the U.S. Department of Health and Human Services transitioned from a direct ordering process for COVID-19 monoclonal antibody therapeutics (mAbs) to a state/territory-coordinated distribution system. The new system will help ensure consistent availability of COVID-19 mAbs and provide health departments with the flexibility to get these critical drugs where they are needed most. Learn More >>
August 27, 2021 - FDA and ASPR announce resumption in use and distribution of bamlanivimab/etesevimab in certain states.
Learn More »
August 20, 2021 - FDA and ASPR announce the shelf-life extension of bamlanivimab under Emergency Use Authorization for bamlanivimab and etesevimab administered together, extending the shelf life from 12 months to 18 months. Learn More »
June 25, 2021 - Distribution of bamlanivimab/etesevimab paused on a national basis until further notice.
Learn More »June 15, 2021 - Distribution of bamlanivimab/etesevimab paused to Rhode Island in addition to Arizona, California, Florida, Indiana, Oregon, Washington, Illinois and Massachusetts. Learn More »May 26, 2021 - Distribution of bamlanivimab/etesevimab paused to Arizona, California, Florida, Indiana, Oregon, and Washington in addition to Illinois and Massachusetts.
Learn More »May 21, 2021 - Distribution of bamlanivimab/etesevimab is paused to Massachusetts in addition to Illinois.
Learn More »May 7, 2021 - Distribution of bamlanivimab/etesevimab is paused to Illinois.
Learn More »
The United States Government (USG) is responsible for the allocation and distribution of monoclonal antibody (mAb) therapeutics for the treatment of COVID-19 as per the Emergency Use Authorizations (EUA) issued by the U.S. Food and Drug Administration (FDA). The USG has developed a process for sites to directly order from the distributor, AmerisourceBergen (ABC).
Eligible administration sites must work with their state or territory’s department of health to obtain COVID-19 monoclonal antibody therapeutics.
Home | Contact Us | Accessibility | Privacy Policies | Disclaimer | HHS Viewers & Players | HHS Plain Language
Assistant Secretary for Preparedness and Response (ASPR), 200 Independence Ave., SW, Washington, DC 20201
U.S. Department of Health and Human Services | USA.gov |
HealthCare.gov in Other Languages